| Assessment Status | Rapid Review Complete |
| HTA ID | 23009 |
| Drug | Durvalumab |
| Brand | Imfinzi® |
| Indication | Durvalumab in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with unresectable or metastatic biliary tract cancer. |
| Assessment Process | |
| Rapid review commissioned | 20/02/2023 |
| Rapid review completed | 16/03/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab used in combination with gemcitabine and cisplatin compared with the current SOC (gemcitabine and cisplatin). |
